Cargando…

Value of (11)C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases

PURPOSE: The most common disadvantage of (11)C-choline positron emission tomography and computed tomography (PET/CT) in diagnosing early-stage prostate cancer (PCa) is its poor sensitivity. In spite of many efforts, this imaging modality lacks the ideal parameter of choline metabolism for the diagno...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Shuoming, Fu, Hongliang, Liu, Changming, Zhu, Ziqiang, Zhang, Jiabin, Weng, Wubin, Kang, Jian, Liu, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882704/
https://www.ncbi.nlm.nih.gov/pubmed/33598428
http://dx.doi.org/10.3389/fonc.2020.600380
_version_ 1783651100854845440
author Zhou, Shuoming
Fu, Hongliang
Liu, Changming
Zhu, Ziqiang
Zhang, Jiabin
Weng, Wubin
Kang, Jian
Liu, Qiang
author_facet Zhou, Shuoming
Fu, Hongliang
Liu, Changming
Zhu, Ziqiang
Zhang, Jiabin
Weng, Wubin
Kang, Jian
Liu, Qiang
author_sort Zhou, Shuoming
collection PubMed
description PURPOSE: The most common disadvantage of (11)C-choline positron emission tomography and computed tomography (PET/CT) in diagnosing early-stage prostate cancer (PCa) is its poor sensitivity. In spite of many efforts, this imaging modality lacks the ideal parameter of choline metabolism for the diagnosis of PCa, and the single metabolic parameter, that is, maximal standardized uptake value (SUVmax), based on this imaging modality is insufficient. (11)C-choline PET/CT-based multi-metabolic parameter combination can help break this limitation. MATERIALS AND METHODS: Before surgery, SUVmax of choline, which is the most common metabolic parameter of (11)C-choline PET/CT, mean standardized uptake value (SUVmean), prostate-to-muscle (P/M) ratio, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from 74 patients with histologically proven PCa were quantified. A total of 13 patients with focal chronic prostatitis without severe features and 30 patients with benign prostate hyperplasia were used for comparison. Univariable and multivariable analyses were performed to compare the patient characteristics and metabolic parameters of (11)C-choline PET/CT. The performance of single parameters and the combination of parameters were assessed by using logistic regression models. RESULTS: The comparable c-statistics, which mean the area under the ROC curve in the logistic regression model, of SUVmax, SUVmean, and P/M ratio are 0.657, 0.667, and 0.672, respectively. The c-statistic significantly rose to 0.793 when SUVmax and SUVmean were combined with the P/M ratio. This parameter combination performed the best for PCa cases with all biochemical recurrence risks and for PCa patients grouped by different risk. The greatest improvement over a single parameter, such as P/M ratio, was noted in the group of low-risk PCa, with values of 0.535 to 0.772 for the three-parameter combination. And in the histopathological level, the Ki-67 index is positively correlated with the P/M ratio (r=0.491, p=0.002). CONCLUSION: P/M ratio is a more ideal parameter than SUVmax as a single parameter in early-stage PCa diagnosis. According to our data, the combination of SUVmax, SUVmean, and P/M ratio as a composite parameter for diagnosis of early stage PCa improves the diagnostic accuracy of (11)C-choline PET/CT.
format Online
Article
Text
id pubmed-7882704
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-78827042021-02-16 Value of (11)C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases Zhou, Shuoming Fu, Hongliang Liu, Changming Zhu, Ziqiang Zhang, Jiabin Weng, Wubin Kang, Jian Liu, Qiang Front Oncol Oncology PURPOSE: The most common disadvantage of (11)C-choline positron emission tomography and computed tomography (PET/CT) in diagnosing early-stage prostate cancer (PCa) is its poor sensitivity. In spite of many efforts, this imaging modality lacks the ideal parameter of choline metabolism for the diagnosis of PCa, and the single metabolic parameter, that is, maximal standardized uptake value (SUVmax), based on this imaging modality is insufficient. (11)C-choline PET/CT-based multi-metabolic parameter combination can help break this limitation. MATERIALS AND METHODS: Before surgery, SUVmax of choline, which is the most common metabolic parameter of (11)C-choline PET/CT, mean standardized uptake value (SUVmean), prostate-to-muscle (P/M) ratio, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) from 74 patients with histologically proven PCa were quantified. A total of 13 patients with focal chronic prostatitis without severe features and 30 patients with benign prostate hyperplasia were used for comparison. Univariable and multivariable analyses were performed to compare the patient characteristics and metabolic parameters of (11)C-choline PET/CT. The performance of single parameters and the combination of parameters were assessed by using logistic regression models. RESULTS: The comparable c-statistics, which mean the area under the ROC curve in the logistic regression model, of SUVmax, SUVmean, and P/M ratio are 0.657, 0.667, and 0.672, respectively. The c-statistic significantly rose to 0.793 when SUVmax and SUVmean were combined with the P/M ratio. This parameter combination performed the best for PCa cases with all biochemical recurrence risks and for PCa patients grouped by different risk. The greatest improvement over a single parameter, such as P/M ratio, was noted in the group of low-risk PCa, with values of 0.535 to 0.772 for the three-parameter combination. And in the histopathological level, the Ki-67 index is positively correlated with the P/M ratio (r=0.491, p=0.002). CONCLUSION: P/M ratio is a more ideal parameter than SUVmax as a single parameter in early-stage PCa diagnosis. According to our data, the combination of SUVmax, SUVmean, and P/M ratio as a composite parameter for diagnosis of early stage PCa improves the diagnostic accuracy of (11)C-choline PET/CT. Frontiers Media S.A. 2021-02-01 /pmc/articles/PMC7882704/ /pubmed/33598428 http://dx.doi.org/10.3389/fonc.2020.600380 Text en Copyright © 2021 Zhou, Fu, Liu, Zhu, Zhang, Weng, Kang and Liu http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhou, Shuoming
Fu, Hongliang
Liu, Changming
Zhu, Ziqiang
Zhang, Jiabin
Weng, Wubin
Kang, Jian
Liu, Qiang
Value of (11)C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases
title Value of (11)C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases
title_full Value of (11)C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases
title_fullStr Value of (11)C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases
title_full_unstemmed Value of (11)C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases
title_short Value of (11)C-Choline PET/CT-Based Multi-Metabolic Parameter Combination in Distinguishing Early-Stage Prostate Cancer From Benign Prostate Diseases
title_sort value of (11)c-choline pet/ct-based multi-metabolic parameter combination in distinguishing early-stage prostate cancer from benign prostate diseases
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7882704/
https://www.ncbi.nlm.nih.gov/pubmed/33598428
http://dx.doi.org/10.3389/fonc.2020.600380
work_keys_str_mv AT zhoushuoming valueof11ccholinepetctbasedmultimetabolicparametercombinationindistinguishingearlystageprostatecancerfrombenignprostatediseases
AT fuhongliang valueof11ccholinepetctbasedmultimetabolicparametercombinationindistinguishingearlystageprostatecancerfrombenignprostatediseases
AT liuchangming valueof11ccholinepetctbasedmultimetabolicparametercombinationindistinguishingearlystageprostatecancerfrombenignprostatediseases
AT zhuziqiang valueof11ccholinepetctbasedmultimetabolicparametercombinationindistinguishingearlystageprostatecancerfrombenignprostatediseases
AT zhangjiabin valueof11ccholinepetctbasedmultimetabolicparametercombinationindistinguishingearlystageprostatecancerfrombenignprostatediseases
AT wengwubin valueof11ccholinepetctbasedmultimetabolicparametercombinationindistinguishingearlystageprostatecancerfrombenignprostatediseases
AT kangjian valueof11ccholinepetctbasedmultimetabolicparametercombinationindistinguishingearlystageprostatecancerfrombenignprostatediseases
AT liuqiang valueof11ccholinepetctbasedmultimetabolicparametercombinationindistinguishingearlystageprostatecancerfrombenignprostatediseases